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Much remains unknown concerning the mechanism
by which the splicing machinery pinpoints short
exons within intronic sequences and how splicing
factors are directed to their pre-mRNA targets. One
probable explanation lies in differences in chromatin
organization between exons and introns. Proteomic,
co-immunoprecipitation, and sedimentation ana-
lyses described here indicate that SF3B1, an essen-
tial splicing component of the U2 snRNP complex, is
strongly associated with nucleosomes. ChIP-seq
and RNA-seq analyses reveal that SF3B1 specifically
binds nucleosomes located at exonic positions.
SF3B1 binding is enriched at nucleosomes posi-
tioned over short exons flanked by long introns
that are also characterized by differential GC con-
tent between exons and introns. Disruption of
SF3B1 binding to such nucleosomes affects splicing
of these exons similarly to SF3B1 knockdown.
Our findings suggest that the association of SF3B1
with nucleosomes is functionally important for
splice-site recognition and that SF3B1 conveys
splicing-relevant information embedded in chro-
matin structure.INTRODUCTION
An increasing body of evidence suggests that the chromatin
landscape is intrinsically intertwined with transcription and
RNA processing (Alexander and Beggs, 2010; Goldstrohm
et al., 2001; Keren-Shaul et al., 2013; Kornblihtt, 2006; Luco
et al., 2011). These connections are evident at the very basic
level of nucleosome positioning across genes and in the
intricate post-transcriptional modification of nucleosome com-
ponents. The connection between chromatin structure and
splicing was first suggested by the discovery that nucleosomes
tend to be positioned over exons rather than flanking intronic
regions (Schwartz et al., 2009; Spies et al., 2009). Subse-618 Cell Reports 11, 618–629, April 28, 2015 ª2015 The Authorsquently, it was demonstrated that trimethylation of lysine 36
on histone 3 marks exonic nucleosomes and is involved in
the recruitment of splicing factors (de Almeida et al., 2011;
Luco et al., 2010). Several studies have shown that splicing fac-
tors associate with histones containing specific modifications,
usually via an adaptor factor that modulates the interaction
(Luco et al., 2011; Schwartz and Ast, 2010). For example, the
association of U2 small nuclear ribonucleoprotein particle
(snRNP) components with trimethylation of lysine 4 on histone
3 is mediated through CHD1, which increases splicing effi-
ciency (Sims et al., 2007). Other splicing machinery compo-
nents, such as SR proteins and the U1 snRNP associated
protein Prp40, bind to the C-terminal domain of RNA polymer-
ase II (Pol II) during transcription (Goldstrohm et al., 2001; Mor-
ris and Greenleaf, 2000; Yuryev et al., 1996), and the elongation
rate of Pol II affects splicing of certain exons (de la Mata et al.,
2003; Dujardin et al., 2013). Since splicing is coupled to tran-
scription, these observations are in line with the premise that
chromatin structure, together with the transcription machinery,
directs the spliceosome to exon-intron junctions, thus enabling
a rapid and precise splicing process. Despite these clues, the
molecular mechanisms that link chromatin architecture to the
splicing machinery remain obscure.
In our exploration of the interaction between chromatin and
splicing factors, we found that SF3B1 strongly associates with
mononucleosomes. SF3B1 is a key component of the U2 snRNP
complex; it binds the branchpoint adenosine in early stages of
spliceosome assembly and facilitates the formation of the com-
plex responsible for splicing (Gozani et al., 1998; Lardelli et al.,
2010; Warkocki et al., 2009). In vitro splicing assays show that
SF3B1 is required for the progression of the splicing reaction
(Wang et al., 1998), and its phosphorylation is crucial for the tran-
sition to active splicing (Bessonov et al., 2010). Recently, muta-
tions in SF3B1 were observed in patients with hematological
malignancies, and these are associated with cancer progression
(Bonnal et al., 2012; Gentien et al., 2014). Three landmark publi-
cations showed that mutations inSF3B1 that are associated with
chronic lymphocytic leukemia and myelodysplastic disorders
result in aberrant splicing of a sub-population of exons (Quesada
et al., 2012; Wang et al., 2011; Yoshida et al., 2011). The contri-
bution of these mutations to cancer development is not fully
understood.
SF3B1 is observed in the chromatin-containing fraction of nu-
clear purifications (Eto et al., 2010) and interacts with chromatin
remodelers (Cavella´n et al., 2006; Isono et al., 2005). The Lu¨hr-
mann lab recently showed that the active phosphorylated form
of SF3B1 is associated with chromatin via RNA (Girard et al.,
2012). These data led us to focus on SF3B1 as a possible
conveyer of chromatin configuration information to splicing
function. In a recent study (Alajem et al., 2015), we developed
an assay called differential chromatin-associated proteins (D-
CAPs) for the identification of chromatin proteins that are differ-
entially bound to chromatin in two cell types or under two sets of
conditions that utilizes high-definition mass spectrometry (Dutta
et al., 2012; Zhang et al., 2010). Using this assay, we found that
numerous splicing factors are associated with chromatin regard-
less of the cell type and that a majority of these factors belong to
the U2 snRNP protein complex. We further confirmed this asso-
ciation by direct reciprocal pull-downs of nucleosome-enriched
nuclear extracts. We found that the association of SF3B1 with
nucleosomes did not depend on RNA or on interactions with
large protein complexes. We mapped the genome-wide posi-
tions of SF3B1-associated nucleosomes using chromatin
immunoprecipitation followed by high-throughput sequencing
(ChIP-seq). Our analysis shows that SF3B1-associated nucleo-
somes are enriched in exonic relative to flanking intronic regions.
Moreover, this enrichment differed between two biologically
distinct groups of exons. Examining splicing patterns by high-
throughput RNA sequencing (RNA-seq) in untreated cells and
cells treated with small interfering RNA (siRNA) designed to
knock down SF3B1 expression indicated that splicing of
exons embedded inside SF3B1-associated nucleosomes was
more often altered in SF3B1-deficient cells. Disruption of
SF3B1 association with nucleosomes selectively altered the
splicing pattern of the SF3B1-bound exons. Our findings provide
a better understanding of the crosstalk between chromatin and
splicing and suggest that SF3B1 is involved in mediating this
crosstalk.
RESULTS
High-Resolution Mass Spectrometry Reveals RNA-
Dependent Association of Splicing Factors with
Nucleosomes
In order to identify the proteins that interactmost directly with nu-
cleosomes, we recently developed a simple biochemical method
based on brief chromatin digestion with micrococcal nuclease
(MNase). Briefly, nuclei purified from cells are washed four times
within 150 mM KCl buffer to remove soluble nucleoplasmic pro-
teins and proteins that are loosely bound to chromatin. Next, the
nuclei are subjected to a brief MNase digestion optimized to
release chromatin-associated proteins. Proteins are identified
using high-definition mass spectrometry (Dutta et al., 2012;
Zhang et al., 2010). This method was used to identify D-CAPs
in undifferentiated mouse embryonic stem cells (ESCs) and in
mouse ESCs differentiated to neuronal progenitor cells (NPCs)
(Alajem et al., 2015). In this study, we were interested in chro-
matin association regardless of differentiation effects; therefore
we used the D-CAP assay to identify proteins bound to chro-
matin in both ESCs and NPCs. To determine whether proteinswere directly associated with chromatin or associated via RNA
(e.g., through nascent transcripts being processed co-transcrip-
tionally), we carried out the D-CAP assay in the absence or in the
presence of RNase treatment. Of the proteins detected, we
investigated 330 proteins that appeared in the untreated sam-
ples of both ESC and NPC cell lines (Table S1); 28 of these are
known splicing factors. Figure 1 lists the chromatin-associated
splicing factors grouped by function: 11 factors are part of
snRNP protein complexes, four are Sm proteins auxiliary to
snRNPs, seven are hnRNP proteins, three are RNA helicases,
and three are splicing regulatory proteins. Strikingly, seven of
the snRNP factors and one RNA helicase are known to belong
to or associate with the U2 snRNP complex, and almost all are
associated independently of RNA. This suggests that the U2
snRNP components bind chromatin directly, either separately
or as a complex. With the exception of Snrnp200, the U1- and
U5-related snRNP factors associated with chromatin in an
RNA-dependent manner. Most of the hnRNPs and splicing
regulatory factors showed some degree of RNA-dependent
chromatin association. It was difficult to determine whether
RNA-dependent associations of splicing factors with chromatin
were mechanistically relevant or simply due to residual spliceo-
somal remnants tethered to chromatin by nascent RNA tran-
scripts. To address this issue, we focused on the association
of U2 snRNP complex with chromatin.
SF3B1 Associates with Nucleosomes Independently
of RNA
To determine whether the same associations observed in ESCs
and NPCs by the D-CAP assay are also present in a human cell
line (HeLa), and to validate the direct association of the U2
snRNP complex with chromatin, we adopted a similar protocol
to achieve a mononucleosome-enriched sample from HeLa
cells. After MNase treatment, the majority of DNA fragments
are 147 bp, the length of a fragment wrapped around a single
nucleosome indicating an enrichment of mononucleosomes
(Figure 2A). We initially immunoprecipitated histone H2B in
order to pull down nucleosomes together with their associated
proteins and examined the presence of SF3B1 by western
blot as a measure of the amount of U2 snRNP complex. This
experiment indicated a strong association of SF3B1 with H2B
(Figure 2B). Then, we immunoprecipitated histone H3 and
SF3B1 and probed these fractions for five different U2 snRNP
components and one U1 snRNP factor (SNRPA). The U2 snRNP
components displayed different degrees of association with
nucleosomes, whereas SNRPA was not associated at all (Fig-
ure 2C). The factors most strongly associated with nucleo-
somes were SF3B1 and SF3A1, as is most apparent in the H3
pull-down untreated lane. The spliceosomal factors examined
showed strong associations with SF3B1 probably as they are
part of a large protein complex. The immunoprecipitation
conditions were stringent and no crosslinking reagents were
used, arguing that the observed interactions are biologically
relevant.
We also examined whether the associations between splicing
factors and nucleosomes in HeLa cells were via an RNA mole-
cule (e.g., U2 snRNA) by performing immunoprecipitation assays
with and without RNase A digestion. Equivalent amounts ofCell Reports 11, 618–629, April 28, 2015 ª2015 The Authors 619
Figure 1. Chromatin-Associated Splicing Factors Identified by D-CAP
Mass spectrometry results listing splicing associated factors that were identified byD-CAP assay as chromatin-associated in both cell lines: ESCs andNPCs. The
right column details weather the chromatin association was maintained after RNase A digestion. The factors are grouped according to function.SF3B1 were precipitated with anti-histone H3 antibody in the
presence and absence of RNase; however, the association of
SF3B3 was slightly reduced, whereas the association of SF3A1
diminished considerably and SF3B4 was entirely undetectable
when samples were treated with RNase (Figure 2C). RNA diges-
tion also reduced the extent of the association of the snRNP fac-
tors with SF3B1 to some extent, but the association of SF3B1
with H3 remained intact. Since SF3B1 exhibited a strong associ-
ation with two nucleosomal proteins, we assume that it is asso-
ciated with mononucleosomes. The association of SF3B1 with
H3 was maintained after DNase digestion and ethidium bromide
treatment eliminating the possibility of a DNA-dependent associ-
ation (Figure S1). In support of this hypothesis, SF3B1 has been
implicated in engaging with chromatin by several other studies
(Cavella´n et al., 2006; Convertini et al., 2014; Eto et al., 2010).
Therefore, we focused much of our effort on investigating the
role of SF3B1 as a potential mediator between splicing and
chromatin.620 Cell Reports 11, 618–629, April 28, 2015 ª2015 The AuthorsSF3B1 Localizes with Nucleosome Complexes
We attempted to ascertain whether SF3B1 was associated with
nucleosomes through a specific histone tail modification using
co-immunoprecipitation (co-IP) assays and histone tail modifica-
tion peptide arrays.We did not identify histonemodifications that
specifically correlate with SF3B1 binding (data not shown). It is
possible that the nucleosomal association of SF3B1 is mediated
through a large protein complex interaction; for example, the
entire spliceosome may associate with the nucleosome. To
evaluate this, we either mildly or extensively digested nuclei
extracted from HeLa cells with MNase (Figure 3A, upper and
lower panels, respectively). We then fractionated these extracts
by ultra-centrifugation sedimentation on a sucrose gradient;
DNA purified from each fraction was resolved by gel electro-
phoresis. Mild digestion with MNase led to an enrichment of
polynucleosomes, whereas extensive digestion with MNase
led to an enrichment of mononucleosomes. We pooled fractions
containing small protein complexes and are enriched with
Figure 2. SF3B1 Is Associated with Nucleo-
somes Independently of RNA
(A) Purified HeLa cells nuclei were digested with
MNase. DNA was purified from MNase digestion
supernatant (lane S), soluble chromatin released
to the supernatant (lane input), and nuclei pellet
harboring mainly insoluble chromatin (lane P),
DNA size is displayed in base-pares (lane M).
Purified DNA was subjected to gel electropho-
resis. DNA fragments representing mono-di-tri.
nucleosome ladder.
(B) Immunoprecipitation of themononucleosomal-
enriched chromatin was performed with an
anti-histone H2B antibody and a nonspecific
immunoglobulin G (IgG) as control. Western blot-
ting was performed with the indicated antibodies.
(C) Immunoprecipitation of the same input was
performed with antibodies against SF3B1, histone
H3, and non-specific IgG; input was either di-
gested or not with RNase A. Western blotting was
performed with the indicated antibodies.mononucleosomes and fractions enriched with polynucleo-
somes that contain large protein complexes (Figure 3A,
‘‘Mono’’ and ‘‘Poly,’’ respectively) and subjected the pools to
RNase A treatment and co-IP. Significantly more SF3B1 was
pulled down together with histone H3 in the Mono pool when
these fractions were enriched with mononucleosomes and
in the Poly pool when these fractions were enriched with poly-
nucleosomes, indicating that the determining factor for the
association of SF3B1 with nucleosomes is the abundance of nu-
cleosomes (Figure 3B). Other components of the U2 snRNP
complex, SF3B3 and SF3A1, did not exhibit the same phenom-
enon; the difference in MNase treatment did not affect their
respective association with nucleosomes (Figure 3B). Without
MNase digestion the sedimentation profiles of each of these
three factors were similar to that of the U2 snRNP complex (Beh-
zadnia et al., 2006) (Figure S1C). These results support the notion
that SF3B1 is strongly bound to nucleosomes, but not as part of
the large spliceosomal complex.
SF3B1 Is Associated with Nucleosomes Residing on
Exonic DNA
Next, we sought out to determine whether SF3B1 is associated
with nucleosomes positioned in specific genomic locations.
Therefore, we sequenced the DNA from mononucleosome-en-Cell Reports 11, 618–6riched fractions (isolated as in Figure 2A)
with or without immunoprecipitation
with an anti-SF3B1 antibody. The seq-
uencing yielded 81 million reads of DNA
fragments wrapping mononucleosomes
pulled down by SF3B1 (SF3B1) and 71
million reads of total mononucleosome-
associated DNA fragments (input), 80%
of which were uniquely mapped to hg18
genome assembly. The read scores on
each genome coordinate of SF3B1 data
were normalized to the coordinate scores
of the input data to eliminate bias arisingfrom primary chromatin landscape and to allow us to focus
only on SF3B1-enriched positions. SF3B1-enriched nucleo-
somes were identified across the genome using HOMER soft-
ware (Heinz et al., 2010) to measure the accumulation of peaks
on introns, exons, and intergenic regions relative to the size of
each genomic segment. This analysis showed that SF3B1 was
associated mainly with nucleosomes bound to genes rather
than intergenic regions and that binding of SF3B1 was enriched
by 2-fold on coding exon in relation to introns (Figure 4A). As
SF3B1 appears to bind preferentially to exons, it might function
in the exon recognition process.
For this reason, we focused our analysis on better character-
izing the associated exons, we aligned SF3B1-enriched positions
on all unique exons derived from RefSeq genes (180,000 exons;
Table S2) and their flanking intronic regions. We found an 5%
enrichment of SF3B1 binding on exons compared to flanking re-
gions (Figure 4B). The observed enrichment of this analysis is
different than that of genomic segment analysis (shown in Fig-
ure 4A), since it calculates the mean signal over a narrow window
surrounding the splice sites and does not account for the size of
the entire segment. We also examined the same data aligned
to the 30 splice site (SS) and the 50 SS of the flanking introns
and observed that SF3B1 is enriched on nucleosomes located
over exonic sequences. We observed a small sub-population of29, April 28, 2015 ª2015 The Authors 621
Figure 3. SF3B1 Localizes with Nucleosome Complexes
Purified nuclei fromHeLa cells were digested byMNase with either 0.075 U/106 nuclei (+) or with 20 U/106 nuclei (+++), and protein complexes were separated on
a 5%–25% sucrose gradient.
(A) After proteinase K digestion, DNA from each fraction was purified and subjected to gel electrophoresis.
(B) Mono (+: fractions 10-13, +++: fractions 9-12) and Poly (+: fractions 25-28, +++: fractions 24-27) fractions were pooled as indicated in (A). Each pool was
immunoprecipitated with an anti-histone H3 antibody and a nonspecific IgG as control. The samples were subjected to western blotting with the indicated
antibodies.SF3B1-associated nucleosomes located slightly upstream of the
30 SS. However, the resolution of MNase-sequencing is insuffi-
cient to identify short elements such as the branch site or the pol-
ypyrimidine track (Figures S2A and S2B).
Next, we analyzed the association of SF3B1 with exons of two
different exon-intron architectures. One is a group of exons con-
taining higher GC content than their flanking introns; these exons
are characterized by long flanking introns (differential GC con-
tent). The other group of exons has similar GC content to that
of their flanking introns; these exons are characterized by short
flanking introns (level GC content). These two groups are recog-
nized differently by the splicing machinery (Amit et al., 2012). In
exons with differential GC content, SF3B1 was enriched by
26% compared to the flanking regions, whereas in the level
GC content group SF3B1 was enriched by 5% (Figures 4C
and 4D). We also analyzed the enrichment of SF3B1 on a group
of exons that were reported to be susceptible to splicing
changes due to mutations in SF3B1 that have been linked
with chronic lymphocytic leukemia (Ferreira et al., 2014). The
enrichment of SF3B1 on these exons in relation to flanking622 Cell Reports 11, 618–629, April 28, 2015 ª2015 The Authorsintronic regions is35%,which is significantly higher than a con-
trol of multiple random selections of the same size group (Fig-
ure 4E). Although this is a group of only 115 exons, the trend of
enrichment is very clear. Taken together, these results imply
that SF3B1 marks the genomic locations of short exonic se-
quences flanked by long intronic sequences and that the splicing
regulation of some of these exons may be significant in the
development and the progression of certain hematological
malignancies.
We analyzed the genomic characteristics of a group of exons
that are highly enriched (5-fold) with SF3B1 (701 exons) and
compared these to those of a group that did not exhibit any
SF3B1 enrichment. Exons were identified from clustering of the
SF3B1 nucleosomal immunoprecipitation data (Figure S2C).
There were no significant differences in methylation, splice-site
score, or alternative/constitutive ratio between the two groups
(Figures S2F–S2H). However, we found elevated H3K4me3
levels at the 30 ends of introns upstream of SF3B1-enriched
exons compared to the unenriched group (Figure S2D), although
the signal is spread across a region of over 400 bp.
Figure 4. SF3B1 Is Associated with Nucleo-
somes Residing on Exonic DNA
HeLa nuclei were digested with MNase under
conditions in which >90% of the DNA was cleaved
into 150-bp mononucleosomal fragments. Sol-
uble chromatin (input) was released from the
nuclei followed by RNase A digestion. DNA frag-
ments were purified from samples immunopre-
cipitated with or without anti-SF3B1 antibody
and subjected to deep sequencing. Fragments
precipitated with anti-SF3B1 antibody and total
DNA reads were mapped to the human genome
(hg18 assembly).
(A) SF3B1 read peaks were normalized to input
read peaks, normalized peaks that overlapped
with genomic segments were identified with
HOMER tools and are displayed as observed
relative to expected normalized to each segment
size.
(B) Normalized SF3B1/Input signal was measured
across all unique exons annotated in RefSeq. The
graphs in this and latter panels show the fre-
quencies of SF3B1-bound nucleosomes on the
75-bp at exon 50 and 30 ends and in flanking in-
tronic regions of sizes indicated on each graph.
The frequencies are in arbitrary units (A.R.).
(C and D) Frequencies of SF3B1-bound nucleo-
somes on exons with (C) differential GC content
and (D) level GC content.
(E) Exons derived from genes reported to show
splicing changes related to SF3B1 mutations
occurring in chronic lymphocytic leukemia (Fer-
reira et al., 2014) and in a 103 multiple random
control exon group. Frequencies were normalized
to the value in the first position.
(F) Exons derived from genes grouped based on
expression levels. Frequencieswere normalized to
the value in the first position.
Error bars represent SEM.Finally, we evaluated the enrichment of SF3B1 on exons as a
function of expression level. For this purpose, we divided genes
on the basis of transcript expression levels in HeLa cells ob-
tained by RNA-seq. Exons were grouped based on the quartile
of expression level of the gene they reside in. SF3B1 enrichment
was most pronounced on the group of exons that were not tran-
scribed, progressively decreased within the first three quartiles
of expression, and remained the same at the two highest quar-
tiles of expression (Figure 4F). This suggests that SF3B1 is pre-
loaded on nucleosomes prior to transcription and that as the
gene is transcribed, SF3B1 detaches from the nucleosome
and likely traverses to the nascent pre-mRNA transcript. The
lack of difference in SF3B1 signal between the top two quartiles
of expression suggests that at a certain point, the rate of SF3B1
loading is similar to the rate of dissociation.
The Association of SF3B1 with Nucleosomes Affects
Splicing
In order to determine whether the splicing of the exons tethered
to nucleosomes is regulated by SF3B1, we knocked down
the expression of SF3B1 in HeLa cells by siRNA treatment
(Figure 5A). We then evaluated whole-transcriptome splicingchanges when SF3B1 levels were decreased by subjecting total
RNA extracted from control and siRNA-treated samples to deep
sequencing. We obtained 383 million paired-end reads, 80% of
which were uniquely mapped to hg18 genome assembly. We
identified 10,657 cassette exons with differences in inclusion
by more than 10% using the SpliceTrap software (Wu et al.,
2011) (Table S3). The inclusion of the majority of the affected
cassette exons (92%) was decreased in SF3B1-knockdown
(SF3B1-KD) cells, affirming that SF3B1 is essential for exon
recognition of these alternatively spliced exons. We then evalu-
ated 32 individual splicing events by RT-PCR; 90% were vali-
dated in trend compared to RNA-seq data analysis (Figure S3A).
We also analyzed the changes in RNA expression levels between
wild-type and SF3B1-KD of all components of the spliceosome
as depicted by Wahl et al. and obtained from Hegele et al. (He-
gele et al., 2012; Wahl et al., 2009). We found no significant
changes in the expression of these genes between wild-type
and SF3B1-KD (Table S4), implying that most of the changes
in splicing observed are due to direct effects of SF3B1 depletion
rather than to changes in expression of other genes.
Next, we examined the enrichment of SF3B1-associated nu-
cleosomes on exons that were significantly affected by SF3B1Cell Reports 11, 618–629, April 28, 2015 ª2015 The Authors 623
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KD (over 30% change in inclusion) compared to unaffected
exons (under 5% change in inclusion) (Figure 5B). Exons sensi-
tive to diminished levels of SF3B1 were more often occupied
by SF3B1-associated nucleosomes than exons that were not
altered in SF3B1-deficient cells. This result implies that the
coupling of SF3B1 with exonic nucleosomes is important for
the splicing regulation of these exons.
To further substantiate this premise, we searched for a way to
disrupt the association between SF3B1 and nucleosomes. We
treated HeLa cells with chemicals known to disturb specific
cellular processes. Interestingly, chemicals that alter chromatin
compaction, especially histone deacetylase inhibitors, trichosta-
tin A (TSA), sodium butyrate (NaB), and valproic acid (VPA), had
the strongest effects on the SF3B1-nucleosome association
(Figures S3B and S3C). TSA, which promotes histone hyper-
acetylation that results in chromatin relaxation (Marks et al.,
2001), disrupted the co-IP of histone H3 with SF3B1 in a dose-
dependent manner (Figure 5C). We also examined the associa-
tion of SF3B1 with nucleosomes in HEK293 cells treated with
TSA and observed the same disruption of the association as in
HeLa cells (Figure S3D). We subdivided the ChIP-seq data into
clusters of exons with varying SF3B1 enrichment and inter-
sected the highly enriched and the unenriched clusters with
the KD affected group of exons (Figure S4A). We measured, by
qRT-PCR, the effect of TSA treatment and of treatment with
siRNA targeting SF3B1 on the splicing of ten exons: five taken
from the enriched sets and five from the unenriched sets (Figures
5D and 5E). All the examined exons had decreased inclusion
levels in cells treated with SF3B1-targeting siRNA; however,
only the exons taken from the SF3B1-enriched cluster were
affected by TSA. We also performed the same analysis in cells
treated with two additional histone deacetylase inhibitors, NaB
and VPA, and also examined the effect of DMSO (used as
vehicle) and 5,6-dichlorobenzimidazole 1-b-D-ribofuranoside
(DRB) (transcription inhibitor) treatments as controls. NaB
and VPA had effects on splicing that were similar to those of
TSA (Figure S4D). DMSO and DRB treatments had almost
no effect on the tested splicing events. This further supports
the idea that the association of SF3B1with nucleosomes located
on exons assists the splicing machinery in the recognition of
such exons.Figure 5. The Association of SF3B1 with Nucleosomes Affects Splicing
(A) SF3B1 expression was knocked down using siRNA targeting SF3B1; contr
examined by western blotting with the indicated antibodies. The level of SF3B1
(B) mRNAs of siRNA-treated and control cells were analyzed using RNA-seq, a
inclusion) were compiled. As in Figure 4, frequencies of SF3B1-bound nucleos
Frequencies were normalized to the value in the first position.
(C) HeLa cells were treated with indicated amounts of TSA or were untreated (UT
nonspecific IgG as control, followed by western blotting with the indicated antib
(D) Inclusion levels of ten exons were measured by qRT-PCR after treatment wi
control siRNA.
(E) Inclusion levels of the same exons were determined after treatment with 750
controls.
(F) mRNAs of TSA-treated and untreated cells were analyzed with RNA-seq. Grou
were compiled. Frequencies of SF3B1-bound nucleosomes are displayed on ex
position.
(G) Venn diagram depicts the overlap between the exons affected by SF3B1-KD a
2.2 3 1016).Next, we evaluated splicing in untreated cells and cells treated
with TSA by RNA-seq.We obtained 140million single-end reads,
60%of which were uniquely mapped to hg18 genome assembly.
Using the SpliceTrap software (Wu et al., 2011), we identified
3,926 cassette exons that changed their inclusion level by
more than 10% and 1,277 that displayed over 30% changes in
inclusion level (Table S5), confirming the previously reported in-
fluences of TSA treatment on the splicing process (Kuhn et al.,
2009; Schor et al., 2009, 2012). We examined the enrichment
of SF3B1-associated nucleosomes on exons that were affected
by TSA (over 30% change in inclusion) and on TSA-unaffected
exons (under 5% change in inclusion) (Figure 5F). TSA preferen-
tially affected the set of exons that were also enriched with
SF3B1-bound nucleosomes: there was approximately 45%
overlap between the two sets (Fisher’s exact test, p < 2.2 3
1016) (Figure 5G). These results support the notion that the
binding of SF3B1 to a nucleosome positioned on an exon en-
hances the recognition of that exon by the spliceosome.
DISCUSSION
Here, we show that SF3B1, a key component of the spliceo-
some, is associated with mononucleosomes that are preferen-
tially positioned over exons. Previous studies had indicated
that SF3B1 is present in chromatin fractions of postnatal mouse
testes (Eto et al., 2010) and that splicing factors are associated
with specific histone modifications (Convertini et al., 2014; de Al-
meida et al., 2011; Luco et al., 2010).
Several factors belonging to the U2 snRNP complex associate
with chromatin in general and specifically with histones (Sims
et al., 2007). Our mass spectrometry study of chromatin-associ-
ated proteins also indicated that U2 snRNP complex compo-
nents interact directly with chromatin; other spliceosomal snRNP
components such as SNRPA and EFTUD2 exhibited RNA-
dependent association with chromatin. A recently published
analysis of proteins that interact with histone H1.0 (Kalashnikova
et al., 2013) supports our observation that the association of
SF3B1 with nucleosomes like that of other U2 snRNP compo-
nents is not dependent on RNA. Many of the splicing factors
that are associated with chromatin are related to the recognition
of the branch site. This implies that when the 30 ends of certainol cells were treated and with a control siRNA. Proteins were extracted and
was quantified by ImageJ.
nd groups of affected exons (>0.3 D inclusion) and unaffected exons ( 0.05 D
omes on exons and flanking regions in the SF3B1-KD groups are displayed.
) for 16 hr. Samples were immunoprecipitated with an anti-SF3B1 antibody or
odies.
th SF3B1 siRNA; data were normalized to inclusion levels in cells treated with
ng/ml TSA for 16 hr, and data were normalized to inclusion levels of untreated
ps of affected exons (>0.3D inclusion) and unaffected exons (<0.05D inclusion)
ons and flanking regions. Frequencies were normalized to the value in the first
nd by treatment with TSA. *** denotes statistical significance of the overlap (p <
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introns emerge from Pol II, U2 snRNPmoves from its location on
the ‘‘exonic nucleosome’’ to the pre-mRNA to facilitate splicing.
In our analysis of the U2 snRNP factors bound to nucleo-
somes, SF3B1 was the most abundant. Since SF3B1 was not
disassociated from nucleosomes by RNase digestion and sedi-
mented together with nucleosomes, we hypothesize that SF3B1
recruits the rest of U2 snRNP complex to the nucleosome. Girard
et al. showed that phosphorylated SF3B1 and the active form of
Pol II are present in chromatin fractionation of HeLa nuclei,
arguing that phosphorylated SF3B1 is associated with active
transcription (Girard et al., 2012). In addition, they showed that
association of phosphorylated SF3B1 with chromatin is RNA
dependent and reaffirmed that it is the phosphorylated form of
SF3B1 that is present in active spliceosome complexes (Besso-
nov et al., 2010). Given that we examined total SF3B1, which
consists of all phosphorylation states, these results together
with our findings suggest that SF3B1 phosphorylation triggers
the transition of nucleosome-bound SF3B1 to nascent RNA in
order to recruit the U2 snRNP complex to exons.
There is large difference in splicing dynamics in vitro and
in vivo. In cell-free systems, splicing of transcripts generated
by Pol II occurs over 15 to 60 min (Das et al., 2006), whereas in
live cells, b-globin introns are transcribed and efficiently excised
in 20–30 s (Martin et al., 2013). Two interdependent nuclear
states are likely to be responsible for directing the splicing ma-
chinery and immensely improving splicing efficiency: the
coupling of splicing to transcription (Listerman et al., 2006;
Luco et al., 2011) and the tendency of nucleosomes to reside
in exonic genomic regions (Schwartz et al., 2009). Our
genome-wide analyses revealed that SF3B1 is associated with
nucleosomes residing over exons. This is probably not a general
phenomenon for all exons, as only a subset of exons tether
nucleosomes that are highly enriched with SF3B1. We show
that nucleosomes that associate with SF3B1 have an even
higher exonic occupancy. Thus, SF3B1might separate ‘‘exonic’’
nucleosomes from ‘‘ordinary’’ nucleosomes. Therefore, we sug-
gest a mechanism in which SF3B1 traverses from an exonic
nucleosome to the branch site of a nascent pre-mRNA transcript
as it is being transcribed in order to facilitate the immediate and
efficient recognition of that exon by the spliceosome.
However, most of the exons associated with SF3B1-bound
nucleosomes have higher levels of GC content compared to their
flanking intronic sequences, a characteristic most commonly
observed for exons flanked by long introns (Amit et al., 2012).
This implies that SF3B1 is recruited to nucleosomes for the pur-
pose of directing the spliceosome to pertinent positions within a
gene, probably prior to transcription. We observed higher levels
of SF3B1 on exons that were not part of actively transcribed
genes. The transcription rate of Pol II was inversely correlated
with SF3B1 binding at lower levels of expression. In the two high-
est quartiles of expression, there were no differences in SF3B1
enrichment. This suggests that the rate of SF3B1 dissociation
from the nucleosome to bind to the nascent pre-mRNA transcript
is equal to rate of a SF3B1 loading on the exonic nucleosome for
these highly expressed genes.
In order to elucidate why SF3B1 binds preferentially to certain
exons rather than others, we used RNA-seq to compare splicing
in control cells and in SF3B1-KD cells. We found that reduction in626 Cell Reports 11, 618–629, April 28, 2015 ª2015 The AuthorsSF3B1 levels resulted in diminished splicing and a decline in the
recognition of thousands of exons. Interestingly, nucleosomes
coupled with SF3B1 were more abundant on exons that were
most effected by SF3B1 KD. Similarly, disturbing the SF3B1-
nucleosome bond resulted in the downregulation of a large
number of exons that exhibited the same enrichment in
SF3B1-associated nucleosomes. Moreover, the recognition of
632 exons was significantly affected by both SF3B1 KD and
nucleosomal detachment, providing further evidence that regu-
lation of splicing of a subset of exons is reliant on the proximity
of SF3B1 to their genomic location.
Recently, mutations in SF3B1 have been linked to various
types of cancer (Bonnal et al., 2012), and these mutations are
correlated with poor prognosis in patients with chronic lympho-
cytic leukemia and myelodysplastic disorders (Quesada et al.,
2012; Yoshida et al., 2011). Whether the pathogenesis of these
mutations is a consequence of reduced levels of functional
protein or dominant-negative effects remains unclear. Most re-
ported mutations in SF3B1 gene are located within the 22
carboxy-terminal HEAT repeats that mediate protein-protein in-
teractions (Groves and Barford, 1999; Rossi et al., 2011; Xing
et al., 2006), and thus suggest a mechanistic failure in splicing.
Hence, it is feasible that these mutations disrupt the interaction
of SF3B1 with nucleosomes, subsequently interfering with
splicing of a group of exons and contributing to cancer progres-
sion. This idea is supported by findings that show splicing
regulation is altered in subjects carrying these mutations
(Wang et al., 2011) and that changes occur in relatively small
groups of splicing events (Ferreira et al., 2014), similar to the ef-
fect we observe when we disturbed the association of SF3B1
with nucleosomes.
Our findings reveal that SF3B1 is a mediator that connects the
splicing machinery with chromatin structure. Previous studies
revealed that factors associated with U1 snRNP bind to the
CTD domain of Pol II (Goldstrohm et al., 2001; McCracken
et al., 1997). The ‘‘commitment complex’’ in which U1 binds
the 50 end of an intron together with U2 snRNP and U2AF1/2
that bind the 30 end of that intron is likely made possible by inter-
action of Poll II and an exonic nucleosome characterized by an
interaction with SF3B1 (Roberts et al., 1998). The Pol II complex
and the exonic nucleosome each harbor complementary snRNP
components, thus allowing for the speedy and accurate recogni-
tion of exons. Our data shed light on how splicing is achieved
within 20–30 s in vivo.EXPERIMENTAL PROCEDURES
Cell Maintenance
HeLa cells were cultured in DMEM with 10% fetal calf serum, 0.29 mg ml1
L-glutamine, 100 U ml1 penicillin, 0.1 mg ml1 streptomycin, and 1 U ml1
nystatin at 37C in a humidified atmosphere with 5% CO2.Nuclei Isolation
Cells were trypsinized and washed with PBS, then suspended in buffer 1
(60 mM KCl, 15 mM NaCl, 5 mM MgCl2, 0.1 mM EGTA, 15 mM Tris-HCl [pH
7.5]) supplemented with 0.5 mM DTT, 0.1 mM PMSF, 13 complete protease
inhibitor (CPI), and incubated in 0.2% IGEPAL CA-630 (NP-40). After incuba-
tion for 10 min, residual NP-40 was cleared by centrifugation on a 1.2-M su-
crose cushion.
Identification of Chromatin-Associated Proteins Identified by
High-Resolution Mass Spectrometry
Nuclei freshly isolated from ESCs or NPCs were washed four times in MNase
digestion buffer without MNase (10 mM Tris-HCl [pH 8], 5 mM CaCl2, 150 mM
KCl, 0.1 mM PMSF, and protease inhibitor cocktail 1:100), resuspended in
MNase digestion buffer with or without RNase (10 ng/ml, Sigma-Aldrich),
rotated for 30 min at 4C, and centrifuged (500 3 g, 4C, 5 min). Nuclei were
then subjected to MNase treatment (4.5 U/ml MNase, Worthington) in MNase
Digestion Buffer. Reactions were stopped by adding 103 MNase stop buffer
(100 mM Tris HCl [pH 7.5], 100 mM EDTA, 10 mM EGTA) followed by centrifu-
gation (13,000 3 g, 4C, 10 min). Supernatants were collected and subjected
to mass spectrometry analyses as described in Alajem et al., 2015 (Supple-
mental Experimental Procedures). To verify the MNase digestion, DNA was
purified from the pellets by phenol-chloroform extraction and ethanol precip-
itation and electrophoresed.
MNase Digestion
Nuclei were suspended in MNase digestion buffer (0.32 M sucrose, 50 mM
Tris-HCl [pH 7.5], 4 mM MgCl2, 1 mM CaCl2) supplemented with 0.1 mM
PMSF. MNase (10 U/106 nuclei, Worthington) was added, and samples were
incubated at 37C for 10 min. The reaction was stopped by the addition of
1 mM EDTA. Nuclei were then sedimented by centrifugation, and nuclei and
supernatant were used for experiments.
Co-IP
MNase-digested nuclei were suspended in immunoprecipitation (IP) buffer
(50 mM HEPES [pH 7.6], 500 mM LiCl, 1 mM EDTA, 0.7% DOC, 1% NP-40,
0.1% SDS, 13 CPI) and rotated for 1 hr at 4C, followed by centrifugation
10,000 3 g for 10 min. This supernatant is denoted as ‘‘input.’’ Indicated
antibodies (4 mg) were added to each input sample and rotated overnight
at 4C. Protein A beads (50 ml, Dynabeads Invitrogen) were washed and
added to each sample and rotated for 4 hr at 4C. Beads were washed
four times with IP buffer and once with 0.5 ml RNase A buffer (PBS,
0.02% Tween 20, CPI, 0.1 mM PMSF). Samples were re-suspended in
450 ml RNase A buffer and 1 ml of 10 mg/ml RNase A (Sigma-Aldrich)
and incubated for 30 min at 37C. All samples were washed another three
times with 0.5 ml IP buffer. Protein was eluted from the beads by adding
100 ml PBS and 20 ml 63 SDS sample buffer (272 mM Tris-HCl [pH 6.8],
30% glycerol, 12% SDS, 20% b-mercaptoethanol, 0.01% bromophenol
blue) and incubating in a thermo-shaker for 15 min at 75C with vigorous
shaking. The supernatant was moved to a new tube and boiled for 5 min
at 100C.
Western Blots and Antibodies
Proteins were separated by SDS-PAGE on 4%–20% polyacrylamide gradient
gels and transferred to 0.45-mmnitrocellulose membranes (Whatman Protran).
The membranes were incubated with the appropriate primary and secondary
antibodies and washed with TBS-Tween 20. Horseradish-peroxidase-conju-
gated secondary antibodies were detected by SuperSignal West Pico Chemi-
luminescent Substrate (Thermo Scientific PI-34080). Antibodies used were
anti-SAP155 (MBL; D221-3), anti-H3 (Abcam; ab1791), anti-H2B (Abcam;
ab1790), anti-SF3B4 (Abcam; ab11803), anti-SF3B3 (Proteintech; 14577),
anti-SF3A1 (Proteintech; 15858), anti-SNRPA1 (Proteintech; 17368), anti-
SNRPA (Santa Cruz; sc-376027), anti HSC-70 (Santa Cruz; sc-7298), donkey
anti-rabbit (Abcam; ab97064), and goat anti-mouse immunoglobulin G (Ab-
cam; ab7068).
MNase Digestion and Sucrose Density Gradient Centrifugation
Purified nuclei (1 3 108) resuspended in 1 ml of RSB buffer containing 0.25 M
sucrose, 3 mMCaCl2, and 100 mMwere digested with 5 U of MNase for partial
digestion or with 500 U of MNase for maximum digestion for 15 min at 37C,
and then the reaction was stopped with EDTA and EGTA (to 10 mM final con-
centrations). After centrifugation at 3,500 3 g for 5 min, the nuclear pellet was
resuspended in 0.3 ml of buffer (10 mM Tris-HCl [pH 7.4], 300 mMNaCl, 5 mM
EDTA, 5 mM EGTA), gently rocked for 1 hr at 4C, and centrifuged to obtain
soluble nucleosomes, which were then fractionated through a sucrose density
gradient solution (5 to 25% sucrose, 10 mM Tris-HCl [pH 7.4], 0.25 mM EDTA)containing the indicated concentrations of NaCl at 100,0003 g for 16 hr at 4C
as described by Jeong et al. (2009)
RNA Isolation and RT-PCR Amplification
Cells were harvested using TRI reagent (Sigma-Aldrich), followed by total
RNA extraction. RT-PCRwas performedwith SuperScript III (Life Technologies)
using oligo(dT) reverse primer followed by PCR with Biotools Taq polymerase
and primers complementary to flanking exon (for a list of primers, see Table
S5). qPCR was performed using KAPA SYBR FAST Universal qPCR kit
(KAPA Biosystems) according to the manufacturer’s instructions using
different exon-exon junction primer pairs to amplify the inclusion iso-
form and the skipping isoform. To calculate inclusion level changes upon
treatment of cells with SF3B1 siRNA we used the following equation:
2inclusionCtðcontrolÞinclusionCtðknockdownÞ=2skippingCtðcontrolÞskippingCtðknockdownÞ. All qPCR
reactions were run on a Stratagene Mx3005P thermocycler. Individual primer
sequences are listed in Table S6.
siRNA Treatment
HeLa cells were grown in 3.5-cm plates to a confluence of 40%. Cells were
transfected with 20 nM of a control nontargeting siRNA (Thermo Scientific,
D-001206) or with SF3B1 targeting siRNA (Thermo Scientific, D-020061) for
48 hr using Lipofectamine RNAiMAX transfection reagent (Invitrogen).
Deep Sequencing and Data Analysis
All of the library preparation and deep sequencing was performed by the
Technion Genome Center on the Illumina HiSeq 2000. For ChIP-seq,
MNase-digested DNA fragments (150 bp in size) of SF3B1 pull down
and of input samples were sequenced by single-end 50-bp reads. Reads
from both samples were aligned to hg18 genome assembly using Bowtie
software in default parameters (Langmead et al., 2009). Each read was de-
noted a single score 75 bp from the start of the read, thus marking a single
position as the center of the fragment/nucleosome. Peak distribution was
analyzed by HOMER tools findPeaks.pl and anotatePeaks.pl, and calcu-
lated as the ratio of observed to expected for each entity (Heinz et al.,
2010). Data were then cast upon RefSeq annotated coordinates of all
known exons and 400 bp of respective flanking regions as described by
Gelfman et al. (Gelfman et al., 2013). Each center nucleosome score was
expanded 73 bp upstream and downstream, creating 147-bp segments
representing a nucleosome-binding site. The superposition of scores re-
sulted in nucleosome occupancy peaks across the exon-intron structure.
Scores of each position were averaged in the relevant group of exons
(e.g., all exons, differential GC, level GC, cancer). Next, we applied a
running average of 20-nt windows on the vector of average values for the
exon-intron structure. The average nucleosome occupancy of SF3B1 sam-
ple was normalized to that of the input sample.
Differential and level GC content groups were compiled as described by
Gelfman et al. (Gelfman et al., 2013). In brief, we tagged the locations of G
and C nucleotides across the genome. Next, we measured the GC percentage
of each exon in our list of all known exons derived from RefSeq. We also
measured the GC percentage of 500-bp segments upstream and downstream
of every exon. We performed a chi-square statistical test on data for each
segment to determine whether the GC content of a given exon was signifi-
cantly higher than that of flanking regions (p < 0.05). This test yielded a group
of 21,697 exons with differential GC content and a group of 23,696 exons with
level GC content. SF3B1 enrichment was calculated in each group as
described for the ‘‘all exons’’ group.
For RNA-seq, total RNAwas extracted from siRNA-treated and control cells.
RNA quality was determined by gel electrophoresis. mRNA was isolated using
poly(A) selection. Sequencing was performed using 100-bp paired-end reads
from SF3B1-KD and control cells and using 50-bp single-end reads of TSA-
treated and untreated cells. Approximately 260 million reads were obtained
for each end of each sample in high quality as determined by FastQC software.
Reads were aligned to hg18 genome assembly using Bowtie software with
default parameters, and splicing analysis was performed using SpliceTrap
(v0.90.5) software with default parameters (Cutoff-M, Junction reads-5) (Wu
et al., 2011). SpliceChange software was employed to determine splicing
changes between samples using default parameters.Cell Reports 11, 618–629, April 28, 2015 ª2015 The Authors 627
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